| ABCB6 mutations cause ocular coloboma L Wang, F He, J Bu, Y Zhen, X Liu, W Du, J Dong, JD Cooney, SK Dubey, ... The American Journal of Human Genetics 90 (1), 40-48, 2012 | 109 | 2012 |
| Mutant IDH inhibits IFNγ–TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma MJ Wu, L Shi, J Dubrot, J Merritt, V Vijay, TY Wei, E Kessler, KE Olander, ... Cancer discovery 12 (3), 812-835, 2022 | 93 | 2022 |
| Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling N Li, Y Wang, S Neri, Y Zhen, LWR Fong, Y Qiao, X Li, Z Chen, C Stephan, ... Nature communications 10 (1), 4363, 2019 | 87 | 2019 |
| EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion–positive cholangiocarcinoma Q Wu, Y Zhen, L Shi, P Vu, P Greninger, R Adil, J Merritt, R Egan, MJ Wu, ... Cancer discovery 12 (5), 1378-1395, 2022 | 68 | 2022 |
| A cell-line-specific atlas of PARP-mediated protein Asp/Glu-ADP-ribosylation in breast cancer Y Zhen, Y Zhang, Y Yu Cell reports 21 (8), 2326-2337, 2017 | 67 | 2017 |
| Impairment of autophagosome-lysosome fusion in the buff mutant mice with the VPS33AD251E mutation Y Zhen, W Li Autophagy 11 (9), 1608-1622, 2015 | 51 | 2015 |
| Proteomic analysis of the downstream signaling network of PARP1 Y Zhen, Y Yu Biochemistry 57 (4), 429-440, 2018 | 44 | 2018 |
| Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma Q Wu, H Ellis, G Siravegna, AG Michel, BL Norden, F Fece de la Cruz, ... Clinical Cancer Research 30 (1), 198-208, 2024 | 23 | 2024 |
| Site-specific analysis of the Asp-and Glu-ADP-ribosylated proteome by quantitative mass spectrometry P Li, Y Zhen, Y Yu Methods in enzymology 626, 301-321, 2019 | 22 | 2019 |
| Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer P Li, Y Zhen, C Kim, Z Liu, J Hao, H Deng, H Deng, M Zhou, XD Wang, ... Science Advances 9 (43), eadg7752, 2023 | 15 | 2023 |
| EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion–positive cholangiocarcinoma. Cancer Discov. 2022; 12 (5): 1378–1395. doi: 10.1158 … Q Wu, Y Zhen, L Shi, P Vu, P Greninger, R Adil CD-21-1168, 0 | 9 | |
| FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma Y Zhen, K Liu, L Shi, S Shah, Q Xu, H Ellis, ER Balasooriya, J Kreuzer, ... Nature Communications 15 (1), 3805, 2024 | 4 | 2024 |
| Nimbolide targets RNF114 to induce the trapping of PARP1 and poly-ADP-ribosylation-dependent DNA repair factors P Li, Y Zhen, C Kim, H Deng, H Deng, XD Wang, T Qin, Y Yu BioRxiv, 2022.10. 04.510815, 2022 | 3 | 2022 |
| Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets V Vijay, N Karisani, L Shi, YH Hung, P Vu, P Kattel, L Kenney, J Merritt, ... bioRxiv, 2024 | 2 | 2024 |
| Nimbolide analogs and methods of use thereof Y Yu, QIN Tian, Z Yuanli, P Li, C Kim, H Deng, D Hejun | 2 | 2022 |
| The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations ER Balasooriya, Q Wu, H Ellis, Y Zhen, BL Norden, RB Corcoran, ... Clinical Cancer Research 30 (10), 2181-2192, 2024 | 1 | 2024 |
| Construction of recombinant plasmid pCMV-Myc-PIASx? and its protein expression J LI, J ZHANG, Y ZHEN, N YANG, X LI Journal of Jilin University (Medicine Edition), 2006 | 1 | 2006 |
| Nimbolide analogs and methods of use thereof Y Yu, T Qin, Z Yuanli, P Li, KIM Chiho, D Heping, D Hejun US Patent App. 18/260,653, 2024 | | 2024 |
| Abstract B023: Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer P Li, Y Zhen, C Kim, Z Liu, J Hao, H Deng, H Deng, M Zhou, XD Wang, ... Molecular Cancer Therapeutics 23 (6_Supplement), B023-B023, 2024 | | 2024 |
| Abstract PR002: Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer P Li, Y Zhen, C Kim, Z Liu, J Hao, H Deng, H Deng, M Zhou, XD Wang, ... Molecular Cancer Therapeutics 23 (6_Supplement), PR002-PR002, 2024 | | 2024 |
